X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs TORRENT PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB TORRENT PHARMA DR. REDDYS LAB/
TORRENT PHARMA
 
P/E (TTM) x 27.4 24.9 110.0% View Chart
P/BV x 2.8 6.1 46.3% View Chart
Dividend Yield % 1.0 3.3 30.6%  

Financials

 DR. REDDYS LAB   TORRENT PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
TORRENT PHARMA
Mar-16
DR. REDDYS LAB/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs4,3831,720 254.8%   
Low Rs2,7501,134 242.6%   
Sales per share (Unadj.) Rs920.1394.5 233.2%  
Earnings per share (Unadj.) Rs126.1101.8 123.9%  
Cash flow per share (Unadj.) Rs183.0116.3 157.3%  
Dividends per share (Unadj.) Rs20.0040.00 50.0%  
Dividend yield (eoy) %0.62.8 20.0%  
Book value per share (Unadj.) Rs685.8200.3 342.4%  
Shares outstanding (eoy) m170.61169.22 100.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.93.6 107.2%   
Avg P/E ratio x28.314.0 201.8%  
P/CF ratio (eoy) x19.512.3 158.9%  
Price / Book Value ratio x5.27.1 73.0%  
Dividend payout %15.939.3 40.4%   
Avg Mkt Cap Rs m608,481241,435 252.0%   
No. of employees `00021.710.9 198.9%   
Total wages/salary Rs m31,8748,559 372.4%   
Avg. sales/employee Rs Th7,244.46,129.6 118.2%   
Avg. wages/employee Rs Th1,470.9785.8 187.2%   
Avg. net profit/employee Rs Th992.81,581.3 62.8%   
INCOME DATA
Net Sales Rs m156,97866,764 235.1%  
Other income Rs m2,6932,156 124.9%   
Total revenues Rs m159,67168,920 231.7%   
Gross profit Rs m34,58727,204 127.1%  
Depreciation Rs m9,7052,461 394.4%   
Interest Rs m8241,859 44.3%   
Profit before tax Rs m26,75125,041 106.8%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-1,403 0.0%   
Tax Rs m5,2376,414 81.7%   
Profit after tax Rs m21,51417,224 124.9%  
Gross profit margin %22.040.7 54.1%  
Effective tax rate %19.625.6 76.4%   
Net profit margin %13.725.8 53.1%  
BALANCE SHEET DATA
Current assets Rs m118,20146,622 253.5%   
Current liabilities Rs m68,36832,843 208.2%   
Net working cap to sales %31.720.6 153.8%  
Current ratio x1.71.4 121.8%  
Inventory Days Days6074 80.8%  
Debtors Days Days9779 122.6%  
Net fixed assets Rs m72,26539,029 185.2%   
Share capital Rs m853846 100.8%   
"Free" reserves Rs m111,54831,400 355.3%   
Net worth Rs m117,00933,890 345.3%   
Long term debt Rs m10,69018,637 57.4%   
Total assets Rs m200,10490,136 222.0%  
Interest coverage x33.514.5 231.2%   
Debt to equity ratio x0.10.5 16.6%  
Sales to assets ratio x0.80.7 105.9%   
Return on assets %11.221.2 52.7%  
Return on equity %18.450.8 36.2%  
Return on capital %21.648.5 44.5%  
Exports to sales %46.343.3 106.7%   
Imports to sales %9.06.9 130.4%   
Exports (fob) Rs m72,61828,934 251.0%   
Imports (cif) Rs m14,0504,584 306.5%   
Fx inflow Rs m75,40529,185 258.4%   
Fx outflow Rs m27,1156,021 450.4%   
Net fx Rs m48,29023,165 208.5%   
CASH FLOW
From Operations Rs m40,47627,132 149.2%  
From Investments Rs m-19,421-7,014 276.9%  
From Financial Activity Rs m-17,009-14,352 118.5%  
Net Cashflow Rs m4,0465,767 70.2%  

Share Holding

Indian Promoters % 25.5 71.5 35.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 7.0 76.9%  
FIIs % 35.3 12.6 280.2%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 8.8 173.9%  
Shareholders   75,885 26,511 286.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SHASUN PHARMA  CIPLA  ABBOTT INDIA  UNICHEM LAB  WYETH LTD  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Pharma Stocks Among Top Gainers(01:30 pm)

After opening the day in green, share markets in India witnessed choppy trades and are presently trading marginally above the dotted line.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 22, 2017 02:54 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS